Education
About Us
Working with TipRanks
Follow Us
OncoCyte Corp (OCX)
NASDAQ:OCX
OCX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.92 - $4.75
Previous CloseN/A
Volume14.21K
Average Volume (3M)97.86K
Market Cap
$87.51M
Enterprise Value$36.40M
Total Cash (Recent Filing)-$4.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
May 20, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.40
Shares Outstanding28,599,285
10 Day Avg. Volume48,624
30 Day Avg. Volume97,856
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)80.73
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit49.19
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$4.63Price Target Upside54.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
OncoCyte News
PremiumCompany Announcements
OncoCyte Corp’s Positive Earnings Call Highlights Growth
PremiumCompany Announcements
Oncocyte Corp Reports 2024 Success and 2025 Growth Plans
---
Bulls Say, Bears Say
Bulls Say
Market DisruptionOncocyte has an ambitious plan to upend the current market for transplant rejection testing using donor-derived cell-free DNA (dd-cfDNA).
Product AdoptionThe use of dd-cfDNA as a biomarker for transplant rejection is validated and broadly adopted across transplant centers in the U.S.
Strategic PartnershipsOCX has partnered with Bio-Rad Laboratories to commercialize its GraftAssure and VitaGraft tests and BIO has taken a ~9% stake in OCX.
Bears Say
Cash FlowOCX used ~$5.5M of cash in Q3 and ended Q3'24 with ~$14M of pro-forma cash, which is estimated as ~2-3 quarters of cash runway.
Revenue PerformanceOCX's Q3'24 revenue of $0.1M came in below consensus' $0.2M.
Stock PerformanceShares have traded down 66% since Josh Riggs took the helm on an interim basis.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCX FAQ
What was OncoCyte Corp’s price range in the past 12 months?
OncoCyte Corp lowest stock price was $1.92 and its highest was $4.75 in the past 12 months.
What is OncoCyte Corp’s market cap?
OncoCyte Corp’s market cap is $87.51M.
When is OncoCyte Corp’s upcoming earnings report date?
OncoCyte Corp’s upcoming earnings report date is May 20, 2025 which is in 48 days.
How were OncoCyte Corp’s earnings last quarter?
OncoCyte Corp released its earnings results on Mar 24, 2025. The company reported -$1.93 earnings per share for the quarter, missing the consensus estimate of -$0.4 by -$1.53.
Is OncoCyte Corp overvalued?
According to Wall Street analysts OncoCyte Corp’s price is currently Undervalued.
Does OncoCyte Corp pay dividends?
OncoCyte Corp does not currently pay dividends.
What is OncoCyte Corp’s EPS estimate?
OncoCyte Corp’s EPS estimate is -0.24.
How many shares outstanding does OncoCyte Corp have?
OncoCyte Corp has 28,599,285 shares outstanding.
What happened to OncoCyte Corp’s price movement after its last earnings report?
OncoCyte Corp reported an EPS of -$1.93 in its last earnings report, missing expectations of -$0.4. Following the earnings report the stock price went down -8.709%.
Which hedge fund is a major shareholder of OncoCyte Corp?
Currently, no hedge funds are holding shares in OCX
---
OncoCyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.63 (54.33% Upside)
$4.63 (54.33% Upside)
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.67%
12-Months-Change
Fundamentals
Return on Equity
-910.86%
Trailing 12-Months
Asset Growth
-53.16%
Trailing 12-Months
Company Description
OncoCyte Corp
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
---
OCX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including the launch of GraftAssure, strategic partnerships, clinical advancements, and financial success. However, there are concerns about potential regulatory delays due to external factors. Despite these challenges, the overall outlook remains positive with expectations of growth and expansion.Read More>---
OCX Stock 12 Month Forecast
Average Price Target
$4.63
▲(54.33% Upside)
Technical Analysis
Best Analysts Covering OCX
1 Year
1 Year Success Rate
3/23 ratings generated profit
1 Year Average Return
-50.97%
reiterated a buy rating 9 days ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 13.04% of your transactions generating a profit, with an average return of -50.97% per trade.
---